Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSightâ„¢ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 22, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a…

Click here to view original post